APR 04, 2018 06:00 AM PDT

Proposed New Genetic-Clinical Risk Grouping Model for Prostate Cancer

Precision medicine is changing landscapes in healthcare.  One area of great interest is figuring out better ways to stratify patients into appropriate therapeutic and prognostic categories for their particular cancer.  In the March 2018 publication of the Journal of Clinical Oncology, researchers outlined the results of a new risk group classification, both developed and validated, combining clinical and genomic testing of biopsied localized prostate cancer tissue.  Prostate cancer can be aggressive or indolent; the current guides make it challenging to determine which men to monitor long term and which are at more immediate risk of death from their cancer.

The currently accepted prostate cancer treatment guidelines from the National Comprehensive Cancer Network (NCCN) include prostate-specific antigen (PSA) level, cancer grade and tumor staging as the criteria for assigning cancer patients into risk groups.  These groups have different therapeutic and prognostic implications for patients.  According to the first author of the study, Dr. Daniel Spratt included that the NCCN model is not necessarily designed to identify and predict which men will develop metastases or die of their cancer.

The researchers utilized genetic testing results evaluating the presence of 22 genes known to increase the risk of metastatic disease.  The combination of genes present provided the group an opportunity to evaluate the gene expression for nearly 7,000 men from multiple clinical sites.  Through the analysis of expression patterns, the study authors developed two new clinical-genomic system models for assigning risk to the patients.  One system had three tiers and one system had 6 tiers.  The authors evaluated the men on all three risk grouping models (NCCN, three tiered, and six-tiered) and then compared those results to patient outcomes and development of metastatic disease.  The new risk models were found, however, to be challenging to blend with the traditional NCCN guidelines so the authors have suggested combining them to create a new genomic-clinical system that standardizes the use of the biomarkers.

The results?  There were differences between the models indicating that both proposed tiered systems more accurately predicted/identified men whose disease remained slow growing and those that had more aggressive forms of prostate cancer that progressed and metastasized.  Using the six-tiered system, 67% of men would have been reclassified to the lower-risk slow-growing cancer group, meaning deferred treatment and careful monitoring of the condition.  The benefits include lowering costs, both for the patient (time, side effects, etc.) and for healthcare (fiscal, resources, etc.). 

The new model also identifies a pool of high-risk men whose disease, if only monitored, were likely to die of prostate cancer.  Providers who use these models can more accurately propose near term treatments like radiation or clinical trials and a prognosis that better match the likely progression of their disease. 

There are clear benefits to the new models including increased efficiently and precision in providing prognoses and therapy recommendations for patients; there are also increased costs up front for the healthcare system/patient for the gene expression testing for all newly diagnosed men.  There is also the challenge of creating a consensus on a new usable genetic-clinical risk system; molecular profiling is not a magic bullet and clinical evaluation must be included (PSA and Gleason score). 

Sources: Journal of Clinical Oncology, ScienceDaily, Biomedicine Hub Review,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
OCT 18, 2019
Cancer
OCT 18, 2019
New anticancer agent discovered
A new study published in the Journal of the American Chemical Society showcases research from Purdue University on the development of an anticancer agent t...
OCT 18, 2019
Drug Discovery & Development
OCT 18, 2019
Promising Drug Encourages Survival in Pancreatic Cancer
Building on almost 20 years of research, a phase 1 clinical trial drug for pancreatic cancer, named ‘AZD1775’, shows promising initial results ...
OCT 18, 2019
Cancer
OCT 18, 2019
Women with sleep apnea have higher rates of cancer
New research published in the European Respiratory Journal analyzed data on 20,000 adults with sleep apnea to conclude that women with severe sleep apnea h...
OCT 18, 2019
Cancer
OCT 18, 2019
Eat more flavonoids!
An apple a day keeps the doctor away? New research published in Nature Communications suggests that there might be some truth to that old saying. But it&rs...
OCT 18, 2019
Cancer
OCT 18, 2019
Urine test detects cancer: watch out for blue pee!
New research from MIT engineers and Imperial and published in Nature Nanotechnology could change the way to detect cancer. The study highlights the develop...
OCT 18, 2019
Cancer
OCT 18, 2019
The golden future of cancer treatment
A study published recently in Chemistry -- A European Journal features research on the golden cancer treatments of the future – literally. Current me...
Loading Comments...